Effect of Pioglitazone, Quercetin and Hydroxy Citric Acid on Extracellular Matrix Components in Experimentally Induced Non-alcoholic Steatohepatitis

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2015 Nov 12

PMID 26557974

Citations 5

Authors

Surapaneni Krishna Mohan

Vishnu Priya Veeraraghavan

Mallika Jainu

Affiliations

Soon will be listed here.

Abstract

Objectives: Non-alcoholic steatohepatitis (NASH), is an important component of Non-alcoholic fatty liver disease (NAFLD) spectrum, which progresses to the end stage liver disease, if not diagnosed and treated properly. The disproportionate production of pro- and anti-inflammatory adipokines secreted from fat contributes to the pathogenesis of NASH. In this study, the comparative effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix (ECM) component levels were studied in experimentally induced NASH.

Materials And Methods: The experimental protocol consists of using 48 male Wister rats, which were divided into 8 groups. The levels of hyaluronic acid, leptin and adiponectin were monitored in experimental NASH.

Results: The experimental NASH rats treated with pioglitazone showed significant decrease in the levels of hyaluronic acid and significant increase in adiponectin levels when compared to experimentally induced NASH group, but did not show any effect on the levels of leptin. Contrary to these two drugs, viz. pioglitazone and hydroxy citric acid, the group treated with quercetin showed significant decrease in the levels of hyaluronic acid and leptin and significant decrease in adiponectin levels compared with that of experimentally induced NASH NASH group, offering maximum protection against NASH.

Conclusion: Considering our findings, it could be concluded that quercetin may offer maximum protection against NASH by significantly increasing the levels of adiponectin, when compared to pioglitazone and hydroxy citric acid.

Citing Articles

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications.

Sotiropoulou M, Katsaros I, Vailas M, Lidoriki I, Papatheodoridis G, Kostomitsopoulos N Saudi J Gastroenterol. 2021; 27(6):319-330.

PMID: 34810376 PMC: 8656328. DOI: 10.4103/sjg.sjg_249_21.

Comparative In Vitro Evaluation of Antibacterial and Osteogenic Activity of Polysaccharide and Flavonoid Fractions Isolated from the leaves of .

Khlusov I, Avdeeva E, Shupletsova V, Khaziakhmatova O, Litvinova L, Porokhova E Molecules. 2019; 24(20).

PMID: 31614835 PMC: 6832169. DOI: 10.3390/molecules24203680.

Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin.

Al-Muzafar H, Amin K Exp Ther Med. 2018; 16(4):2938-2948.

PMID: 30214514 PMC: 6125847. DOI: 10.3892/etm.2018.6563.

The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease.

Swiderska M, Jaroszewicz J, Stawicka A, Parfieniuk-Kowerda A, Chabowski A, Flisiak R Clin Exp Hepatol. 2017; 3(3):127-134.

PMID: 29062902 PMC: 5649483. DOI: 10.5114/ceh.2017.68466.

Herbal medicines and nonalcoholic fatty liver disease.

Yao H, Qiao Y, Zhao Y, Tao X, Xu L, Yin L World J Gastroenterol. 2016; 22(30):6890-905.

PMID: 27570425 PMC: 4974587. DOI: 10.3748/wjg.v22.i30.6890.

References

Wellen K, Uysal K, Wiesbrock S, Yang Q, Chen H, Hotamisligil G . Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity. Endocrinology. 2004; 145(5):2214-20. DOI: 10.1210/en.2003-1580. View

Haukeland J, Damas J, Konopski Z, Loberg E, Haaland T, Goverud I . Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44(6):1167-74. DOI: 10.1016/j.jhep.2006.02.011. View

Bouloumie A, Marumo T, Lafontan M, Busse R . Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999; 13(10):1231-8. View

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J . Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372(6505):425-32. DOI: 10.1038/372425a0. View

Spiegelman B, Flier J . Obesity and the regulation of energy balance. Cell. 2001; 104(4):531-43. DOI: 10.1016/s0092-8674(01)00240-9. View

Surapaneni K, Jainu M . Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis. Pharmacognosy Res. 2014; 6(2):153-62. PMC: 3996753. DOI: 10.4103/0974-8490.129037. View

Huang X, Fan Y, Zhang H, Wang P, Yuan J, Li M . Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol. 2008; 14(18):2888-93. PMC: 2710733. DOI: 10.3748/wjg.14.2888. View

Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O . Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes. 2003; 52(5):1182-6. DOI: 10.2337/diabetes.52.5.1182. View

Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K . Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005; 25(4):779-86. DOI: 10.1111/j.1478-3231.2005.01064.x. View

10.

Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C . Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology. 2002; 36(2):403-9. DOI: 10.1053/jhep.2002.34738. View

11.

Xu A, Wang Y, Keshaw H, Xu L, Lam K, Cooper G . The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112(1):91-100. PMC: 162288. DOI: 10.1172/JCI17797. View

12.

Tilg H, Hotamisligil G . Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006; 131(3):934-45. DOI: 10.1053/j.gastro.2006.05.054. View

13.

Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N . Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000; 96(5):1723-32. View

14.

Maffei M, Halaas J, Ravussin E, Pratley R, Lee G, Zhang Y . Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995; 1(11):1155-61. DOI: 10.1038/nm1195-1155. View

15.

Fruebis J, Tsao T, Javorschi S, Erickson M, Yen F, Bihain B . Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001; 98(4):2005-10. PMC: 29372. DOI: 10.1073/pnas.98.4.2005. View

16.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

17.

Liou I, Kowdley K . Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006; 40 Suppl 1:S11-6. DOI: 10.1097/01.mcg.0000168644.23697.31. View

18.

Tilg H, Diehl A . Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000; 343(20):1467-76. DOI: 10.1056/NEJM200011163432007. View

19.

Surapaneni K, Jainu M . Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. J Physiol Pharmacol. 2014; 65(1):67-74. View

20.

Tsao T, Murrey H, Hug C, Lee D, Lodish H . Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem. 2002; 277(33):29359-62. DOI: 10.1074/jbc.C200312200. View